Seoul Economic TV reported on October 6, 2026 that policosanol showed signs of cognitive improvement in a clinical study involving middle-aged and older adults. According to the broadcaster, the signal appeared alongside the substance's better-known effect on HDL cholesterol. The report framed the finding as an early indication rather than a confirmed outcome.
Coverage of the same development by other Korean outlets echoed that framing. Hyundai Health News reported that policosanol may both raise HDL and improve cognitive function, describing the cognitive benefit as a possibility rather than an established result.
The reports place the policosanol news within a broader discussion of vascular and metabolic health in aging. Pharm News published commentary from Professor Yoo Byung-wook emphasizing sustained metabolic management as central to brain vascular health, and argued for evidence-based public health medicine. Separate Pharm News coverage examined HDL, noting that the quality of the cholesterol, not only its quantity, is considered key to vascular health, and highlighting lipoprotein physiology and its clinical value.
Together, the items suggest growing Korean medical interest in how lipid and metabolic factors relate to cognitive decline. Seoul Economic TV's report did not provide trial size, duration, or the specific cognitive measures used, and no peer-reviewed publication was cited in the material available. The finding should therefore be read as a preliminary signal from a single reported trial.
What to watch next: whether the trial results are published in full, including participant numbers and cognitive test outcomes, and whether larger studies confirm the effect.
